Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
33,071,678
-
Share change
-
+2,706,920
-
Total reported value
-
$676,319,830
-
Put/Call ratio
-
30%
-
Price per share
-
$20.45
-
Number of holders
-
90
-
Value change
-
+$56,203,015
-
Number of buys
-
58
-
Number of sells
-
22
Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q4 2016
As of 31 Dec 2016,
AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,071,678 shares.
The largest 10 holders included
FMR LLC, Foresite Capital Management II, LLC, Aisling Capital LLC, TLP GROUP LLC, EAGLE ASSET MANAGEMENT INC, VANGUARD GROUP INC, BlackRock Fund Advisors, ADAGE CAPITAL PARTNERS GP, L.L.C., PRICE T ROWE ASSOCIATES INC /MD/, and Foresite Capital Management III, LLC.
This page lists
90
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.